The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Open accessAbstract
Recent advances in mRNA technology and its delivery have enabled mRNA-based therapeutics to enter a new era in medicine. The rapid, potent, and transient nature of mRNA-encoded proteins, without the need to enter the nucleus or the risk of genomic integration, makes them desirable tools for treatment of a range of diseases, from infectious diseases to cancer and monogenic disorders. The rapid pace and ease of mass-scale manufacturability of mRNA-based therapeutics supported the global response to the COVID-19 pandemic. Nonetheless, challenges remain with regards to mRNA stability, duration of expression, delivery efficiency, and targetability, to broaden the applicability of mRNA therapeutics beyond COVID-19 vaccines. By learning from the rapidly expanding preclinical and clinical studies, we can optimise the mRNA platform to meet the clinical needs of each disease. Here, we will summarise the recent advances in mRNA technology; its use in vaccines, immunotherapeutics, protein replacement therapy, and genomic editing; and its delivery to desired specific cell types and organs for development of a new generation of targeted mRNA-based therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationDirect Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Incidence and Outcomes of Acute Lung Injury
Rubenfeld, G. D., Caldwell, E., Peabody, E., Weaver, J., Martin, D. P., Neff, M., Stern, E. J., & Hudson, L. D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050333 · Cited by 3,684
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
Iuliano, A. D., Roguski, K. M., Chang, H. H., Muscatello, D. J., Palekar, R., Tempia, S., Cohen, C., Gran, J. M., Schanzer, D., Cowling, B. J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33293-2 · Cited by 3,019
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
T follicular helper cell biology: a decade of discovery and diseases
Crotty, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.011 · Cited by 1,591
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Self-citationFirst report of autochthonous transmission of Zika virus in Brazil
Zanluca, C., Melo, V. C. A. D., Mosimann, A. L. P., Santos, G. I. V. D., Santos, C. N. D. D., & Luz, K. (2015) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760150192 · Cited by 1,320
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Lipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
Dilliard, S. A., Cheng, Q., & Siegwart, D. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109256118 · Cited by 1,018
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Self-citationModified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Self-citationThe clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775
Self-citationExpression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
mRNA structure regulates protein expression through changes in functional half-life
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L., Nair, S. K., Congdon, K. L., Reap, E. A., Archer, G. E., Desjardins, A., et al. (2015) · Nature · doi:10.1038/nature14320 · Cited by 531
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, Ö., Kranz, L. M., Berger, H., Petschenka, J., et al. (2021) · Science · doi:10.1126/science.aay3638 · Cited by 520
Recent advances in mRNA vaccine technology
Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512
Self-citationModifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
Nance, K. D., & Meier, J. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00197 · Cited by 466
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454
Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S., & Stephan, M. T. (2020) · Nature Communications · doi:10.1038/s41467-020-19486-2 · Cited by 446
Role of CFTR in epithelial physiology
Saint-Criq, V., & Gray, M. A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2391-y · Cited by 433
mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., Parkhurst, M. R., Yossef, R., Lowery, F. J., Jafferji, M. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134915 · Cited by 427
Sebastiani, F., Yanez Arteta, M., Lerche, M., Porcar, L., Lang, C., Bragg, R. A., Elmore, C. S., Krishnamurthy, V. R., Russell, R. A., Darwish, T., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10064 · Cited by 409
Qiu, M., Glass, Z., Chen, J., Haas, M., Jin, X., Zhao, X., Rui, X., Ye, Z., Li, Y., Zhang, F., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020401118 · Cited by 409
Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383
Self-citationIn vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
Rothgangl, T., Dennis, M. K., Lin, P. J. C., Oka, R., Witzigmann, D., Villiger, L., Qi, W., Hruzova, M., Kissling, L., Lenggenhager, D., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00933-4 · Cited by 378
Self-citationTailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Lipid nanoparticle technology for therapeutic gene regulation in the liver
Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376
Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365
Laczkó, D., Hogan, M. J., Toulmin, S. A., Hicks, P., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 363
Self-citationA multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Arevalo, C. P., Bolton, M. J., Le Sage, V., Ye, N., Furey, C., Muramatsu, H., Alameh, M.-G., Pardi, N., Drapeau, E. M., Parkhouse, K., et al. (2022) · Science · doi:10.1126/science.abm0271 · Cited by 358
Self-citationPardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Self-citationDimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
In vivo hematopoietic stem cell modification by mRNA delivery
Breda, L., Papp, T. E., Triebwasser, M. P., Yadegari, A., Fedorky, M. T., Tanaka, N., Abdulmalik, O., Pavani, G., Wang, Y., Grupp, S. A., et al. (2023) · Science · doi:10.1126/science.ade6967 · Cited by 335
Self-citation(1995) · PubMed · Cited by 330
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
Rajasagi, M., Shukla, S. A., Fritsch, E. F., Keskin, D. B., DeLuca, D., Carmona, E., Zhang, W., Sougnez, C., Cibulskis, K., Sidney, J., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567933 · Cited by 309
Davies, J. C., Alton, E. W. F. W., & Bush, A. (2007) · BMJ · doi:10.1136/bmj.39391.713229.ad · Cited by 306
Systemic delivery of factor IX messenger RNA for protein replacement therapy
Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301
Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.018 · Cited by 299
Self-citationTombácz, I., Laczkó, D., Shahnawaz, H., Muramatsu, H., Natesan, A., Yadegari, A., Papp, T. E., Alameh, M.-G., Shuvaev, V., Mui, B. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.004 · Cited by 296
Self-citationElimination of large tumors in mice by mRNA-encoded bispecific antibodies
Stadler, C. R., Bähr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., Karikó, K., Türeci, Ö., & Sahin, U. (2017) · Nature Medicine · doi:10.1038/nm.4356 · Cited by 290
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 282
Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E. (1992) · Science · doi:10.1126/science.1546298 · Cited by 282
Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281
Self-citationVaccination induces HIV broadly neutralizing antibody precursors in humans
Leggat, D. J., Cohen, K. W., Willis, J. R., Fulp, W. J., deCamp, A. C., Kalyuzhniy, O., Cottrell, C. A., Menis, S., Finak, G., Ballweber-Fleming, L., et al. (2022) · Science · doi:10.1126/science.add6502 · Cited by 276
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease
Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., Himansu, S., Caine, E. A., Nunes, B. T. D., Medeiros, D. B. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.040 · Cited by 267
Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes
Theobald, M., Biggs, J., Hernández, J., Lustgarten, J., Labadie, C., & Sherman, L. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.5.833 · Cited by 256
Production of Recombinant Proteins: Challenges and Solutions
Palomares, L. A., Estrada-Mondaca, S., & Ramírez, O. T. (2004) · Recombinant Gene Expression · doi:10.1385/1-59259-774-2:015 · Cited by 256
Kim, S. C., Sekhon, S. S., Shin, W.-R., Ahn, G., Cho, B.-K., Ahn, J.-Y., & Kim, Y.-H. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00171-4 · Cited by 255
Geisbert, T. W., Hensley, L. E., Kagan, E., Yu, E. Z., Geisbert, J. B., Daddario‐DiCaprio, K., Fritz, E. A., Jahrling, P. B., McClintock, K., Phelps, J. R., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/504267 · Cited by 254
GC content shapes mRNA storage and decay in human cells
Courel, M., Clément, Y., Bossevain, C., Foretek, D., Vidal Cruchez, O., Yi, Z., Bénard, M., Benassy, M.-N., Kress, M., Vindry, C., et al. (2019) · eLife · doi:10.7554/elife.49708 · Cited by 250
Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Zhang, H.-X., Zhang, Y., & Yin, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.014 · Cited by 248
Hemophilia A and B: molecular and clinical similarities and differences
Castaman, G., & Matino, D. (2019) · Haematologica · doi:10.3324/haematol.2019.221093 · Cited by 236
Parhiz, H., Shuvaev, V. V., Pardi, N., Khoshnejad, M., Kiseleva, R. Y., Brenner, J. S., Uhler, T., Tuyishime, S., Mui, B. L., Tam, Y. K., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.015 · Cited by 233
Self-citationSchnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 230
The safety of Covid-19 mRNA vaccines: a review
Anand, P., & Stahel, V. P. (2021) · Patient Safety in Surgery · doi:10.1186/s13037-021-00291-9 · Cited by 230
Aldrich, C., Leroux–Roels, I., Huang, K. B., Bica, M. A., Loeliger, E., Schoenborn-Kellenberger, O., Walz, L., Leroux-Roels, G., von Sonnenburg, F., & Oostvogels, L. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.12.070 · Cited by 213
Tales of Detailed Poly(A) Tails
Nicholson, A. L., & Pasquinelli, A. E. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.11.002 · Cited by 209
Current and future influenza vaccines
Yamayoshi, S., & Kawaoka, Y. (2019) · Nature Medicine · doi:10.1038/s41591-018-0340-z · Cited by 203
Immune History and Influenza Vaccine Effectiveness
Lewnard, J. A., & Cobey, S. (2018) · Vaccines · doi:10.3390/vaccines6020028 · Cited by 196
The status of tuberculosis vaccine development
Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M., & Olesen, O. F. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30625-5 · Cited by 196
August, A., Attarwala, H. Z., Himansu, S., Kalidindi, S., Lu, S., Pajon, R., Han, S., Lecerf, J.-M., Tomassini, J. E., Hard, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01573-6 · Cited by 196
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
Martinez, D. R., Schäfer, A., Leist, S. R., De la Cruz, G., West, A., Atochina-Vasserman, E. N., Lindesmith, L. C., Pardi, N., Parks, R., Barr, M., et al. (2021) · Science · doi:10.1126/science.abi4506 · Cited by 188
Self-citationMarcos-Contreras, O. A., Greineder, C. F., Kiseleva, R. Y., Parhiz, H., Walsh, L. R., Zuluaga-Ramirez, V., Myerson, J. W., Hood, E. D., Villa, C. H., Tombacz, I., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912012117 · Cited by 185
Self-citationmRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 182
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
Jiang, L., Berraondo, P., Jericó, D., Guey, L. T., Sampedro, A., Frassetto, A., Benenato, K. E., Burke, K., Santamaría, E., Alegre, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0199-z · Cited by 181
Zhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.003 · Cited by 165
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J.-Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 165
The March Toward Malaria Vaccines
Hoffman, S. L., Vekemans, J., Richie, T. L., & Duffy, P. E. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.09.011 · Cited by 164
Khoryati, L., Pham, M. N., Sherve, M., Kumari, S., Cook, K. D., Pearson, J. T., Bogdani, M., Campbell, D., & Gavin, M. A. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba5264 · Cited by 157
Determinants and implications of mRNA poly(A) tail size – Does this protein make my tail look big?
Jalkanen, A. L., Coleman, S. J., & Wilusz, J. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.05.018 · Cited by 154
Essink, B. J., Chu, L., Seger, W., Barranco, E., Cam, N. L., Bennett, H., Faughnan, V., Pajón, R., Paila, Y. D., Bollman, B. A., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00764-2 · Cited by 154
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Prakash, V., Moore, M., & Yáñez‐Muñoz, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.5 · Cited by 150
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 149
Current Status of Zika Virus Vaccines: Successes and Challenges
Pattnaik, A., Sahoo, B. R., & Pattnaik, A. K. (2020) · Vaccines · doi:10.3390/vaccines8020266 · Cited by 147
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2022) · Nature · doi:10.1038/s41586-021-04231-6 · Cited by 141
Genetic diagnosis of haemophilia and other inherited bleeding disorders
Peyvandi, F., Jayandharan, G. R., Chandy, M., Srivastava, A., Nakaya, S. M., Johnson, M., Thompson, A. R., Goodeve, A. C., Garagiola, I., Lavoretano, S., et al. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01263.x · Cited by 138
Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132
mRNA: Fulfilling the Promise of Gene Therapy
Weissman, D., & Karikó, K. (2015) · Molecular Therapy · doi:10.1038/mt.2015.138 · Cited by 121
Self-citationGulck, E. R. V., Vlieghe, E., Vekemans, M., Tendeloo, V. F. V., de Velde, A. V., Smits, E., Anguille, S., Cools, N., Goossens, H., Mertens, L., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834f33e8 · Cited by 116
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 115
Izikson, R., Brune, D., Bolduc, J.-S., Bourron, P., Fournier, M., Moore, T. M., Pandey, A., Perez, L., Sater, N., Shrestha, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00557-9 · Cited by 112
Montefiori, D. C., Roederer, M., Morris, L., & Seaman, M. S. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000442 · Cited by 110
Wojtczak, B. A., Sikorski, P. J., Fac-Dabrowska, K., Nowicka, A. M., Warmiński, M., Kubacka, D., Nowak, E., Nowotny, M., Kowalska, J., & Jemielity, J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b02597 · Cited by 101
Saunders, K. O., Pardi, N., Parks, R., Santra, S., Mu, Z., Sutherland, L. L., Scearce, R. M., Barr, M., Eaton, A., Hernandez, G. E., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00307-6 · Cited by 97
Self-citationCancer therapy and vaccination
Aly, H. A. A. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.05.014 · Cited by 95
Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria
Raj, D. K., Das Mohapatra, A., Jnawali, A., Zuromski, J., Jha, A., Cham-Kpu, G., Sherman, B., Rudlaff, R. M., Nixon, C. E., Hilton, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2220-1 · Cited by 93
Self-citationA New Era for Rare Genetic Diseases: Messenger RNA Therapy
Martini, P. G. V., & Guey, L. T. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.090 · Cited by 91
Kore, A. R., Shanmugasundaram, M., Charles, I., Vlassov, A. V., & Barta, T. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja901655p · Cited by 90
Synthetic modified messenger RNA for therapeutic applications
Gao, M., Zhang, Q., Feng, X.-H., & Liu, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.020 · Cited by 89
Almási, T., Guey, L. T., Lukacs, C., Csetneki, K., Vokó, Z., & Zelei, T. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1063-z · Cited by 88
HIV mRNA Vaccines—Progress and Future Paths
Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Vaccines · doi:10.3390/vaccines9020134 · Cited by 88
Lorenzi, J. C. C., Trombone, A. P. F., Rocha, C. D., de Almeida, L. P., Lousada, R. L., Malardo, T., Fontoura, I. C., Rossetti, R. A. M., Gembre, A. F., Silva, A. M., et al. (2010) · BMC Biotechnology · doi:10.1186/1472-6750-10-77 · Cited by 84
Pedersen, S. R., Sørensen, M. R., Buus, S., Christensen, J. P., & Thomsen, A. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300555 · Cited by 83
Mu, Z., Wiehe, K. J., Saunders, K. O., Henderson, R. C., Cain, D. W., Parks, R., Martik, D., Mansouri, K., Edwards, R. J., Newman, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110514 · Cited by 83
Self-citationMaximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs
Trepotec, Z., Aneja, M. K., Geiger, J., Hasenpusch, G., Plank, C., & Rudolph, C. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0485 · Cited by 77
Xue, T., Stavropoulos, E., Yang, M., Ragno, S., Vordermeier, M., Chambers, M., Hewinson, G., Lowrie, D. B., Colston, M. J., & Tascon, R. E. (2004) · Infection and Immunity · doi:10.1128/iai.72.11.6324-6329.2004 · Cited by 73
Emerging drugs for treating the acute respiratory distress syndrome
Shaw, T. D., McAuley, D. F., & O’Kane, C. M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591369 · Cited by 68
Therapeutic mRNA delivery to leukocytes
Granot-Matok, Y., Kon, E., Dammes, N., Mechtinger, G., & Peer, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.032 · Cited by 65
The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein
Liou, T. G. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.10.006 · Cited by 64
Hayashi, C. T. H., Cao, Y., Clark, L. C., Tripathi, A. K., Zavala, F. P., Dwivedi, G., Knox, J. J., Alameh, M., Lin, P. J. C., Tam, Y. K., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00577-8 · Cited by 64
Self-citationmRNA Vaccine Protects against Zika Virus
Medina-Magües, L. G., Gergen, J., Jasny, E., Petsch, B., Lopera-Madrid, J., Medina-Magües, E. S., Salas-Quinchucua, C., & Osorio, J. E. (2021) · Vaccines · doi:10.3390/vaccines9121464 · Cited by 54
Jagger, B. W., Dowd, K. A., Chen, R. E., Desai, P., Foreman, B., Burgomaster, K. E., Himansu, S., Kong, W.-P., Graham, B. S., Pierson, T. C., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz338 · Cited by 53
Strenkowska, M., Kowalska, J., Łukaszewicz, M., Zuberek, J., Su, W., Rhoads, R. E., Darżynkiewicz, E., & Jemielity, J. (2010) · New Journal of Chemistry · doi:10.1039/b9nj00644c · Cited by 42
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 39
Russick, J., Delignat, S., Milanov, P., Christophe, O. D., Boros, G., Denis, C. V., Lenting, P. J., Kaveri, S. V., & Lacroix‐Desmazes, S. (2019) · Haematologica · doi:10.3324/haematol.2018.210583 · Cited by 31
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
Larsen, S. E., Baldwin, S. L., & Coler, R. N. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.035 · Cited by 26
Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M. E., Zaks, T. Z., Frederick, J. P., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Global Oncology · doi:10.1200/jgo.2019.5.suppl.93 · Cited by 25
Besser, H., Yunger, S., Merhavi-Shoham, E., Cohen, C. J., & Louzoun, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0595-z · Cited by 22
Kumar, S., Lin, X., Ngo, T., Shapero, B. G., Sou, C., Allen, J. D., Copps, J., Zhang, L., Ozorowski, G., He, L., et al. (2021) · mBio · doi:10.1128/mbio.00429-21 · Cited by 15
Li, L., Zheng, C., La, J., Do, N., Monach, P. A., Strymish, J. M., Fillmore, N. R., & Branch‐Elliman, W. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.026 · Cited by 15
3′-Modification stabilizes mRNA and increases translation in cells
Gampe, C. M., Seila, A. C., Siva, S., Zécri, F. J., & Diener, J. L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.008 · Cited by 11
Waghela, I. N., Mallory, K. L., Taylor, J. A., Schneider, C. G., Savransky, T., Janse, C. J., Lin, P. J. C., Tam, Y. K., Weissman, D., & Angov, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026052 · Cited by 11
Self-citationGebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2021) · doi:10.1101/2021.08.13.456316 · Cited by 8
Fikadu, W., Addissie, A., & Kifle, A. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s416781 · Cited by 7
Cited by
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
HydraRNA: a hybrid architecture based full-length RNA language model
Li, G., Jiang, F., Zhu, J., Cui, H., Wang, Z., & Chen, W. (2025) · Genome Biology · doi:10.1186/s13059-025-03853-7 · Cited by 10
Metadata
- Authors
- Parhiz, H., Atochina-Vasserman, E. N., & Weissman, D.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 403
- Issue
- 10432
- Pages
- 1192-1204
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4392564463
- Cited by
- 279
- References
- 138
- FWCI
- 32.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.